|Mr. Chaim Lebovits||Chief Exec. Officer||1.64M||N/A||1971|
|Dr. Irit Arbel Ph.D., DSc||Co-Founder & Independent Vice Chair of the Board||N/A||N/A||1960|
|Dr. Ralph Z. Kern||Pres & Chief Medical Officer||844.22k||N/A||1958|
|Mr. Uri Yablonka||Exec. VP, Chief Bus. Officer, Sec. & Director||N/A||N/A||1977|
|Dr. Preetam Shah M.B.A., Ph.D.||Exec. VP, CFO & Treasurer||N/A||N/A||1973|
|Dr. David Setboun M.B.A., Pharm.D.||Exec. VP & COO||N/A||N/A||1975|
|Dr. Yael Gothelf||VP of Scientific & Regulatory Affairs||N/A||N/A||N/A|
|Dr. Daniel Offen||Chief Scientific Advisor||N/A||N/A||N/A|
|Mr. Arturo O. Araya||Chief Commercial Officer||N/A||N/A||1971|
|Dr. Stacy R. Lindborg Ph.D.||Exec. VP & Head of Global Clinical Research||N/A||N/A||1971|
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Brainstorm Cell Therapeutics Inc.’s ISS Governance QualityScore as of April 1, 2021 is 6. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 6; Compensation: 8.